Korea PMG Pharmaceutical "Conducting Phase 3 Clinical Trial of Osteoarthritis Treatment 'PK101'"

[Asia Economy Reporter Seo So-jeong] Korea PMG Pharmaceutical announced on the 12th that it is conducting a Phase 3 clinical trial for the osteoarthritis treatment 'PK101'.

PK101 is a non-steroidal anti-inflammatory drug (NSAIDs) product that enhances efficacy while reducing cardiovascular and gastrointestinal side effects. It is a combination of natural medicine and synthetic medicine.

Osteoarthritis is a disease requiring long-term administration in elderly patients, and due to market demand for safer drugs, the market size for natural medicines has recently been increasing.

Korea PMG Pharmaceutical received approval from the Ministry of Food and Drug Safety for the Phase 3 clinical trial of PK101 in December last year and aims to launch the product in 2023.

The Phase 3 clinical trial is being conducted at 10 institutions nationwide targeting patients with knee osteoarthritis to verify the efficacy and safety of PK101. The total number of trial participants is 354. The participating institutions include Jeonbuk National University Hospital, Ajou University Hospital, Busan Paik Hospital, and other 10 centers nationwide specializing in rheumatology.

A PMG Pharmaceutical official stated, "Although the number of osteoarthritis patients is increasing due to population aging and rising obesity, existing osteoarthritis treatments have limitations due to cardiovascular side effects, short half-life, and low therapeutic effect. PK101, a combination of natural medicine and synthetic medicine, offers a new treatment option in the market."

This content was produced with the assistance of AI translation services.